We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




First Known DNA Biomarker Licensed for Use in Determining Drug Response in Multiple Myeloma

By LabMedica International staff writers
Posted on 10 Dec 2012
Empire Genomics (Buffalo, NY, USA) reported it has acquired an exclusive license for patent-pending new genomic biomarkers from Emory University (Atlanta, GA, USA) for use in developing a molecular diagnostic test that could help fulfill a large unmet medical need in determining optimal therapeutic treatment for multiple myeloma (MM) patients. More...


Recent studies have shown that specific genetic biomarkers may identify which patients would benefit from receiving treatment with the various therapies opposed to those that receive no benefit. The investigators are initiating in a phase II biomarker-driven clinical trial using this technology to substantiate its effectiveness to predict outcomes in new generations of MM pharmaceuticals.

“Developing a clinically validated multiple myeloma cancer theranostic assay with informative data would represent a major breakthrough in improving disease management,” said Leon Bernal-Mizrachi, MD, assistant professor of hematology and medical oncology, Emory University School of Medicine. “It would fulfill an unmet medical need to help patients with multiple myeloma better plan treatment options that will help produce the best outcomes.”

MM accounts for approximately 10% of blood based cancers, with an estimated 21,700 new cases and 10,710 deaths in the United States in 2012. MM is a malignant blood cell cancer that is increasing in frequency in the current aging population. While developments in therapeutic treatments have improved the response rate, there are considerable side effects to these very expensive treatments.

Empire Genomics is marketing a genetic test for multiple myeloma that is designed to guide treatments and decrease healthcare costs, while sparing patients the negative consequences of treatments that may not be effective. This new diagnostic test will be the first DNA biomarker test to direct treatment of MM. Empire will also examine the use of this biomarker in lymphoma patients.

“This is a meaningful breakthrough in the area of personalized medicine and we are excited to work with Emory University and Dr. Bernal-Mizrachi to bring it to the market to help oncologists make more informed treatment decisions for this dreadful disease,” said Anthony Johnson, CEO of Empire Genomics.

It is expected that this test will be employed in clinical trials in the future as well as launched through clinical labs in early 2013.

Related Links:

Empire Genomics
Emory University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Immunofluorescence Analyzer
IFA System
New
Automated Immunoassay Analyzer
SuperFlex™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders

Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.